Sorrento Therapeutics Inc (SRNE)

[dia76ca]

PaulSnowman makes some good points!
"Right now Sorrento is lumped in with the rest of the overcrowded Biotech sector with no revenue. Even though unlike most small Biotechs they have revenue from Ztildo and STIX. In STIX case a projected 2022 revenue between 750M-1B might not be far off the mark. We’ll see both a top line readout for MSC (Covid) and full readout / multiple peer reviews for SP102 in the near future. The switch can flip in an instant for a Biotech. Some say its crazy to buy with the SP suppression and downward spiral. I say its crazy not to load up at these levels. Time and patience. See you on the other side."
And...."SP102 will get approval this year or next. Estimated annual revenue for US alone is projected between 6-11B, but lets say 3B. Thats for US alone. Are you with me so far? 3B times 5=15B MC. Following me? Sorrento MC is currently 756M, and SP is 2.20. So with 15B MC the SP would be $43. Thats at a conservative 3B annually for SP. Not including whatever other pipeline items get approval / EUA / partnership / asset sold / licensing / etc… Ji made a grab at Sclilex shares for a reason. its because SP102 is well tolerated, non opioid, and the only non black label, and its 99,9% to get approved. Tutes are loading up, and so should any investor with powder, time, and patience. You can lead a horse to water… Your choice."